TrialsgrambetaRCTs are beautiful

ACTT-1

2020

Remdesivir for the Treatment of COVID-19

In 1,062 hospitalised COVID-19 patients, remdesivir shortened time to recovery compared with placebo.

Result

Primary endpoint: Time to recovery

10 vs 15 days; 28-d mortality 11.4% vs 15.2% (HR 0.73; NS).

Original publication
Subtopic
Antivirals
Design
Double-blind RCT, NIAID
Relevance
Supporting: context rather than must-know.
Source
Beigel JH, et al. N Engl J Med. 2020;383(19):1813-1826.doi 10.1056/NEJMoa2007764

Discussion & critique

Faster recovery without convincing mortality signal; later WHO SOLIDARITY pooling neutral.

Discussed in podcasts